exp3174 has been researched along with thromboxane a2 in 5 studies
| Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (thromboxane a2) | Trials (thromboxane a2) | Recent Studies (post-2010) (thromboxane a2) |
|---|---|---|---|---|---|
| 236 | 29 | 43 | 5,617 | 224 | 429 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brosnihan, KB; Ferrario, CM; Li, P | 1 |
| Casado, S; Castilla, C; Farré, J; Gómez, J; Guerra, JI; Jiménez, AM; López-Farré, A; Marcos, P; Montón, M; Núñez, A; Rico, L; Rodríguez-Feo, JA; Sánchez De Miguel, L | 1 |
| Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR | 1 |
| Bassenge, E; Schwemmer, M; Sommer, O | 1 |
| Böger, RH; Drexler, H; Forssmann, WG; Krämer, C; Luchtefeld, M; Schieffer, B; Schmidt, B; Sunkomat, J; Tsikas, D; Walden, M; Witte, J | 1 |
1 trial(s) available for exp3174 and thromboxane a2
| Article | Year |
|---|---|
Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arachidonic Acid; Biotransformation; Cells, Cultured; Cyclooxygenase 2; Dinoprost; Drug Design; Endothelium, Vascular; Enzyme Activation; Female; Humans; Hypertension; Imidazoles; Inflammation; Intercellular Adhesion Molecule-1; Isoenzymes; Lipopolysaccharides; Losartan; Male; Membrane Proteins; Middle Aged; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Thromboxane A2; Up-Regulation; Vasoconstrictor Agents | 2002 |
4 other study(ies) available for exp3174 and thromboxane a2
| Article | Year |
|---|---|
Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Endothelins; Endothelium, Vascular; Imidazoles; Losartan; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Inbred SHR; Receptors, Prostaglandin; Receptors, Thromboxane A2, Prostaglandin H2; Tetrazoles; Thromboxane A2; Vasoconstriction; Vasoconstrictor Agents | 1998 |
[Effect of losartan on human platelet activation by thromboxane A2].
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adult; Angiotensin II; Humans; Imidazoles; Losartan; Male; Platelet Activation; Receptors, Thromboxane; Tetrazoles; Thromboxane A2 | 2000 |
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan | 2000 |
Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
Topics: Angiotensin Receptor Antagonists; Animals; Arachidonic Acids; Benzimidazoles; Biphenyl Compounds; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imidazoles; Losartan; Phospholipases A; Phospholipases A2; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Thromboxane; Renin-Angiotensin System; Signal Transduction; Tetrazoles; Thromboxane A2 | 2001 |